| Description | The IgG, fc fragment does not bind antigen; however, it does contain the classic antigenic determinants and biological activity with respect to cytotrophic reactions, binding of complement and catabolic rate control.Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and The IgG, fc fragment does not bind antigen; however, it does contain the classic antigenic determinants and biological activity with respect to cytotrophic reactions, binding of complement and catabolic rate control.Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.Product Citations:Franco, Andrea, et al. "Human Fc Receptor–Like 5 Binds Intact IgG via Mechanisms Distinct from Those of Fc Receptors."The Journal of Immunology 190, no. 11 (2013): 5739-5746.Baković, Maja Pučić, et al. "High-Throughput IgG Fc N-Glycosylation Profiling by Mass Spectrometry of Glycopeptides." Journal of proteome research 12, no. 2 (2013): 821-831Barb, Adam W., et al. "NMR Characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation." Biochemistry 51, no. 22 (2012): 4618-4626.Padmanabhan A, et al. Intravenous immunoglobulin for the treatment of severe refractory heparin induced thrombocytopenia. Chest, Available online 17 April 2017 in press, corrected proof.Anquetil F, et al. IgM and IgA Rheumatoid Factors Purified from Rheumatoid Arthritis Sera Boost the Fc Receptor– and Complement-Dependent Effector Functions of the Disease-Specific Anti–Citrullinated Protein Autoantibodies. J Immunol. 2015 Apr 15;194(8):3664-74. doi: 10.4049/jimmunol.1402334. Epub 2015 Mar 13.Frank M, et al. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol. 2014 Apr 17;426(8):1799-811. doi: 10.1016/j.jmb.2014.01.011. Epub 2014 Feb 9.Ref:Ricardo, M.J. et al. 1984. Clinical Diagnosis and Management by Laboratory Methods (J.B. Henry, ed.), 860; Poljak, R. J. 1985. Methods Enzymol. 116, 190... Read More | Inquire | Product Application:KNK437 has been used: as a heat shock factor 1 (HSF1) inhibitor to study its effects on the inhibition of viability and apoptosis activation in chemoresistant mice cells as an HSF1 inhibitor to study its effects on viability and apoptosis of colorectal cancer cells as a Product Application:KNK437 has been used: as a heat shock factor 1 (HSF1) inhibitor to study its effects on the inhibition of viability and apoptosis activation in chemoresistant mice cells as an HSF1 inhibitor to study its effects on viability and apoptosis of colorectal cancer cells as a heat shock protein 70 (HSP70) inhibitor to study its effects on glutamine-induced HSP70 and inflammatory mediator release... Read More | Inquire | p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins |